Boehringer Ingelheim International Gmbh

Ablynx N.v.

Beatrijs Strubbe

Marie-Ange Buyse

Stephanie Staelens

Karen Cromie

Vittoria Zinzalla

Klaus-Peter Kuenkele

The invention provides LRP5-binding polypeptides, and more specifically LRP5-binding immunoglobulin single variable domain constructs which can inhibit Wnt signaling pathways. The invention also relates to specific sequences of such polypeptides, methods of their production, and methods of using them, including methods of treatment of diseases such as cancer.

Polypeptides antagonizing Wnt signaling in tumor cells

The invention provides novel biparatopic LRP5/LRP6 cross-reactive binding polypeptides, and more specifically novel biparatopic LRP5/LRP6 cross-reactive immunoglobulin single variable domain constructs which can inhibit Wnt signaling pathways. The invention also relates to specific sequences of such polypeptides, methods of their production, and methods of using them, including methods of treatment of diseases such as cancer.

Biparatopic polypeptides antagonizing Wnt signaling in tumor cells

The invention provides novel LRP5-binding polypeptides, and more specifically novel LRP5-binding immunoglobulin single variable domain constructs which can inhibit Wnt signaling pathways. The invention also relates to specific sequences of such polypeptides, methods of their production, and methods of using them, including methods of treatment of diseases such as cancer.

Growing community of inventors

Oostakker, Belgium

Beatrijs Strubbe